Marketing: Page 8
-
Courtesy of Apellis Pharmaceuticals
Apellis faces safety doubts for fast-selling eye drug
At a medical meeting, the company confirmed seven cases of a rare, but severe, side effect have been reported following treatment with its geographic atrophy drug Syfovre.
By Ben Fidler • Updated July 31, 2023 -
Courtesy of Apellis Pharmaceuticals
Apellis shares sink on reports of rare side effects with new vision loss drug
An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent with testing.
By Ben Fidler • July 17, 2023 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
More convenient form of Roche MS drug succeeds in study
The under-the-skin formulation of Ocrevus can be administered in 10 minutes, versus a longer period for the current intravenous version.
By Kristin Jensen • July 13, 2023 -
Mario Tama via Getty Images
EMA expands probe of possible suicide risk to popular weight loss, diabetes drugs
The European drug regulator says it now has 150 reports of possible cases involving self-injury and suicidal thoughts among people taking GLP-1 medicines like Ozempic.
By Kristin Jensen • July 12, 2023 -
artJazz via Getty Images
Illumina hit by EU with maximum fine for Grail acquisition
The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.
By Susan Kelly • July 12, 2023 -
Justin Sullivan via Getty Images
Bausch + Lomb bulks up OTC business with J&J deal
The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.
By Ned Pagliarulo • July 6, 2023 -
Courtesy of BioMarin Pharmaceutical
With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy
The agency granted a long-awaited clearance last Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.
By Jacob Bell • June 30, 2023 -
Permission granted by Amylyx Pharmaceuticals
Amylyx’s ALS drug gets pushback from European regulators
An EMA committee expressed concern with the main study meant to show Amylyx’s drug is safe and effective. The company now plans to ask for a re-examination of its approval application.
By Jacob Bell • June 23, 2023 -
Kevin Dietsch via Getty Images
As Illumina’s deSouza departs, will Grail go next?
The CEO’s resignation signals a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.
By Susan Kelly • June 12, 2023 -
Sean Gallup via Getty Images
Bayer launches precision health unit in latest digital health venture
The pharma company said it will work with startups and other digital health companies as it builds out the consumer-focused business unit.
By Emily Olsen • June 1, 2023 -
Ground Picture/Shutterstock.com
Sponsored by Veeva2023 Veeva trends in HCP omnichannel engagement report
Boost campaign effectiveness by 23% by synchronizing sales and marketing.
May 30, 2023 -
Rebecca Pifer/BioPharma Dive
House lawmakers, PBM lobby spar over committee hearing
At the latest congressional inquiry into pharmacy benefit managers, lawmakers argued the middlemen profit at the expense of patients and taxpayers.
By Rebecca Pifer • May 25, 2023 -
Permission granted by Amylyx Pharmaceuticals
Amylyx’s ALS drug again surpasses Wall Street expectations
Revenue from the biotech’s ALS therapy Relyvrio totaled $71.4 million in the first quarter, well above analyst estimates and helping the company turn a profit only months into the drug’s launch.
By Jacob Bell • May 11, 2023 -
Scott Olson via Getty Images
Here’s what will change when the COVID public health emergency ends
Vaccines, which have been crucial to curbing the virus’ spread, will remain free for the vast majority of people in the U.S., but over-the-counter tests will no longer be covered for most.
By Shannon Muchmore • May 10, 2023 -
Anna Moneymaker/Getty Images via Getty Images
Abortion providers in 3 states sue over mifepristone restrictions
The lawsuit seeks to remove safety restrictions on mifepristone or, alternatively, prevent further altering of access to the drug.
By Sydney Halleman • May 9, 2023 -
Jeenah Moon via Getty Images
Pfizer turns focus to new drugs as COVID vaccine revenue falls
The drugmaker beat Wall Street’s first quarter forecasts despite a sales drop that puts pressure on it to succeed with upcoming market launches.
By Jonathan Gardner • May 2, 2023 -
Courtesy of Eli Lilly
Lilly plans dash to market for weight loss drug after trial win
The drugmaker will use a priority review voucher in a bid to secure FDA approval of Mounjaro in obesity by late this year or early next.
By Jonathan Gardner • April 27, 2023 -
iStock via Getty Images
Roche’s new eye drug pressures Eylea with strong launch
One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.
By Jonathan Gardner • April 26, 2023 -
Courtesy of Eli Lilly
Lilly sells emergency diabetes drug for $500M
The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.
By Jonathan Gardner • April 24, 2023 -
Michaela Wong/BioPharma Dive
Supreme Court maintains access to abortion pill, blocking restrictions on its use
The stay suspends a Texas judge’s order that invalidated the FDA’s approval of mifepristone, keeping it available while a circuit court hears the case.
By Delilah Alvarado • Updated April 22, 2023 -
Anna Moneymaker/Getty Images via Getty Images
Supreme Court delays decision in battle over abortion pill
An administrative stay of a Texas district court ruling will remain in place through Friday, pushing out a Supreme Court decision in the closely watched case over the drug mifepristone.
By Delilah Alvarado • April 19, 2023 -
Sarah Silbiger via Getty Images
FDA again knocks back Alvotech’s Humira biosimilar
The agency rejected the partners’ copycat version of AbbVie’s blockbuster drug for a second time, citing problems spotted during the inspection of a manufacturing facility.
By Jonathan Gardner • April 14, 2023 -
Novo boosts sales outlook on strong demand for obesity drug
The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.
By Kristin Jensen • April 13, 2023 -
Evelyn Hockstein / Reuters
Federal judge invalidates FDA approval of abortion pill
The April 8 decision by a district court judge in Texas set off a high-profile chain of litigation that has now reached the Supreme Court, whose decision could carry ripple effects for drug regulation more broadly.
By Delilah Alvarado • April 8, 2023 -
Kevin Dietsch via Getty Images
FDA withdraws preterm birth drug’s approval, denying maker’s request for delay
Commissioner Robert Califf and Chief Scientist Namandjé Bumpus determined there was “no justification” for keeping Covis Pharma’s controversial treatment Makena on the market.
By Ned Pagliarulo • April 6, 2023
Previous
